Synthetic Lethality: Identification of effective combination therapies is critical to address drug resistance in cancer treatment, and can also lead to novel therapies toward a target deemed “undruggable” in conventional ways. Paired gRNA library could be used in screening for genetic interactions, and such synergistic gene pairs can be translated into synergistic drug combinations. With pgRNA technology, and extensive experience in both coding and non-coding elements, our platform offers screening for synthetic lethality in unmatched scale and breadth.
CRISPR-empowered Tiling Mutagenesis Combined with Assorted-DNA-fragment Sequencing (CRISTMAS): Using sgRNAs designed for tiling mutagenesis of targeted genes and special algorithm, CRISTMAS allows one to map functional elements of a particular gene at single amino acid resolution, leading to identification of amino acid(s) critical for a function or drug sensitivity/resistance。
EDIGENE BIOTECHNOLOGY USA INC。
245 FIRST STREET, RIVERVIEW II, 18TH FLOORCAMBRIDGE, MA 02142 USA